Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate and iPTH in elderly patients with age-related osteoporosis
IRCT20241108063637N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alendronate in osteoporosis (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoint: intact parathyroid hormone (iPTH). Started Dec 2024; status: completed.
02
Drugs
alendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on IRCT20241108063637N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241108063637N1.